SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors. SB-715992 and docetaxel were dosed by 1-hour intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-715992. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Solid Tumor Cancer

Clinical Trial Details

NCT number	NCT00169520
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	June 2004

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00891761` - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy	Phase 3
Completed	`NCT00046111` - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00119171` - Ispinesib In Combination With Capecitabine In Patients With Solid Tumors	Phase 1
Recruiting	`NCT04354064` - Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting	`NCT02103920` - A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors	N/A
Completed	`NCT00085878` - Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors	Phase 1
Completed	`NCT00085904` - Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas	Phase 1
Completed	`NCT00136513` - SB-743921 In Patients With Solid Tumors	Phase 1
Completed	`NCT06042400` - Trial of Written Exposure for Metastatic Cancer Patients (EASE)	N/A